All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Repurposing major metabolites of lamiaceae family as potential inhibitors of alpha-synuclein aggregation to alleviate neurodegenerative diseases: an in silico approach

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60460709%3A41110%2F25%3A102405" target="_blank" >RIV/60460709:41110/25:102405 - isvavai.cz</a>

  • Alternative codes found

    RIV/60460709:41210/25:102405 RIV/60460709:41340/25:102405

  • Result on the web

    <a href="https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1519145/full" target="_blank" >https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1519145/full</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.3389/fphar.2025.1519145" target="_blank" >10.3389/fphar.2025.1519145</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Repurposing major metabolites of lamiaceae family as potential inhibitors of alpha-synuclein aggregation to alleviate neurodegenerative diseases: an in silico approach

  • Original language description

    Neurodegenerative disorders (NDs) are typically characterized by progressive loss of neuronal function and the deposition of misfolded proteins in the brain and peripheral organs. They are molecularly classified based on the specific proteins involved, underscoring the critical role of protein-processing systems in their pathogenesis. Alpha-synuclein (alpha-syn) is a neural protein that is crucial in initiating and progressing various NDs by directly or indirectly regulating other ND-associated proteins. Therefore, reducing the alpha-syn aggregation can be an excellent option for combating ND initiation and progression. This study presents an in silico phytochemical-based approach for discovering novel neuroprotective agents from bioactive compounds of the Lamiaceae family, highlighting the potential of computational methods such as functional networking, pathway enrichment analysis, molecular docking, and simulation in therapeutic discovery. Functional network and enrichment pathway analysis established the direct or indirect involvement of alpha-syn in various NDs. Furthermore, molecular docking interaction and simulation studies were conducted to screen 85 major bioactive compounds of the Lamiaceae family against the alpha-syn aggregation. The results showed that five compounds (alpha-copaene, gamma-eudesmol, carnosol, cedryl acetate, and spathulenol) had a high binding affinity towards alpha-syn with potential inhibitory activity towards its aggregation. MD simulations validated the stability of the molecular interactions determined by molecular docking. In addition, in silico pharmacokinetic analysis underscores their potential as promising drug candidates, demonstrating excellent blood-brain barrier (BBB) permeability, bioactivity, and reduced toxicity. In summary, this study identifies the most suitable compounds for targeting the alpha-syn aggregation and recommends these compounds as potential therapeutic agents against various NDs, pending further in vitro and in vivo validation.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    10608 - Biochemistry and molecular biology

Result continuities

  • Project

  • Continuities

    S - Specificky vyzkum na vysokych skolach

Others

  • Publication year

    2025

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Frontiers in Pharmacology

  • ISSN

    1663-9812

  • e-ISSN

    1663-9812

  • Volume of the periodical

    16

  • Issue of the periodical within the volume

    APR 16 2025

  • Country of publishing house

    CH - SWITZERLAND

  • Number of pages

    19

  • Pages from-to

  • UT code for WoS article

    001478747300001

  • EID of the result in the Scopus database

    2-s2.0-105004028069